Table 5.
Ceiling for EQ-5D-3L and EQ-5D-5L in nine subgroups and six countries
| Ceiling 3L (% 11111) | Ceiling 5L (% 11111) | Absolute reduction (%) | Percentage reduction (%) | |
|---|---|---|---|---|
| Subgroup | ||||
| Cardiovascular disease | 13.1 | 8.0 | 5.2 | 39.4 |
| COPD/Asthma | 8.5 | 7.0 | 1.5 | 17.2 |
| Depression | 12.0 | 6.4 | 5.6 | 46.7 |
| Diabetes | 33.9 | 28.3 | 5.7 | 16.7 |
| Liver disease | 38.5 | 35.7 | 2.8 | 7.2 |
| Personality disorder | 7.7 | 3.9 | 3.8 | 48.8 |
| RA/Arthritis | 6.5 | 1.9 | 4.6 | 70.8 |
| Stroke | 7.1 | 6.0 | 1.1 | 15.0 |
| Students | 47.0 | 34.3 | 12.6 | 26.9 |
| Country | ||||
| Denmark | 32.8 | 30.4 | 2.3 | 7.1 |
| England | 10.0 | 5.7 | 4.3 | 43.0 |
| Italya | 38.5 | 35.7 | 2.8 | 7.2 |
| Netherlands | 7.8 | 4.0 | 3.8 | 49.0 |
| Poland | 23.6 | 17.6 | 6.0 | 25.4 |
| Scotland | 9.6 | 6.0 | 3.6 | 37.5 |
| Total | 20.2 | 16.0 | 4.2 | 20.8 |
COPD chronic obstructive pulmonary disease, RA rheumatoid arthritis
aIdentical to liver disease cohort